Mi az ára Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) ára $4.64

Mi a Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294 piaci tőkésítése)

Shenzhen Salubris Pharmaceuticals Co., Ltd. piaci tőkésítése (002294) $5.18B

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) Forgalomban Lévő Részvények

Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.

Év	Kintlévő részvények	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

Kintlévő részvények

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	Kintlévő részvények	Különbség	Ország
Intuitive Surgical, Inc. ISRG.US	354.50M	-	US
EssilorLuxottica S.A. EL.PA	461.20M	-	FR
HOYA Corporation 7741.T	-	-	JP
Becton, Dickinson and Company BDX.US	274.79M	-	US
Alcon Inc. ALC.SW	-	-	CH

Vállalat

Kintlévő részvények

Különbség

Ország